Lake Street Capital Cuts ReWalk Robotics (NASDAQ:LFWD) Price Target to $4.50

ReWalk Robotics (NASDAQ:LFWD) had its target price trimmed by Lake Street Capital from $6.00 to $4.50 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

LFWD has been the topic of several other research reports. Laidlaw started coverage on ReWalk Robotics in a research report on Monday, February 10th. They issued a “buy” rating and a $10.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of ReWalk Robotics in a research report on Thursday.

ReWalk Robotics Trading Down 4.1 %

ReWalk Robotics stock opened at $1.77 on Thursday. ReWalk Robotics has a 12 month low of $1.25 and a 12 month high of $7.70. The stock’s 50 day simple moving average is $1.74 and its two-hundred day simple moving average is $2.40. The firm has a market cap of $18.76 million, a PE ratio of -0.71 and a beta of 2.05.

Insider Transactions at ReWalk Robotics

In other ReWalk Robotics news, Director Michael Swinford bought 21,622 shares of ReWalk Robotics stock in a transaction dated Monday, November 25th. The stock was acquired at an average cost of $2.03 per share, with a total value of $43,892.66. Following the purchase, the director now directly owns 65,040 shares in the company, valued at $132,031.20. This represents a 49.80 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Global Fund Lp Lind II sold 381,676 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $3.36, for a total value of $1,282,431.36. Following the transaction, the insider now directly owns 1,049,430 shares of the company’s stock, valued at approximately $3,526,084.80. The trade was a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.50% of the company’s stock.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.